Ivemend

Fosaprepitant, the active ingredient in Ivemend, is a neurokinin‑1 (NK1) receptor antagonist presented as a 150 mg per 100 mL injectable solution for intravenous use. It is employed to prevent both acute and delayed nausea and vomiting associated with chemotherapy in adult cancer patients.

GNH USA supplies Ivemend as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this antiemetic for clinical use. The company adheres to stringent quality standards and offers global logistics support to ensure product integrity during transport.

Fosaprepitant, an NK1 receptor antagonist, is used to control chemotherapy‑induced nausea and vomiting. - Acute chemotherapy‑induced nausea and vomiting: reduces onset of symptoms during the first 24 hours after chemotherapy. - Delayed chemotherapy‑induced nausea and vomiting: lowers incidence of symptoms occurring 24‑120 hours post‑treatment. - Overall CINV management in adult cancer patients: improves patient comfort and supports adherence to chemotherapy regimens.

Fosaprepitant may be associated with a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site pain: mild discomfort at the intravenous site. - Fatigue: transient feeling of tiredness. - Diarrhea: loose stools occurring shortly after administration. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Elevated liver enzymes: increased ALT or AST indicating hepatic stress. - Cardiac arrhythmias: rare occurrences of irregular heart rhythm.

When using Fosaprepitant, clinicians should consider several precautionary measures to ensure patient safety. - Assess patient history: evaluate prior hypersensitivity to NK1 antagonists. - Monitor liver function: check baseline and periodic ALT/AST levels. - Use with caution in renal impairment: adjust supportive care as needed. - Avoid concurrent use with strong CYP3A4 inhibitors: may increase fosaprepitant exposure. - Pregnancy and lactation: avoid unless benefit outweighs potential risk (category unknown). - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Fosaprepitant can affect the metabolism of other medicines, leading to clinically relevant drug‑drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase fosaprepitant plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may substantially reduce efficacy of fosaprepitant.

Moderate Interactions (Monitor Closely): - Sedative agents (e.g., midazolam, opioids): fosaprepitant may increase their plasma levels, requiring dose adjustment. - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Antidepressants metabolized by CYP2D6 (e.g., fluoxetine): monitor for enhanced effects.